Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Forest Laboratories Provides Update on Succession Planning

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Howard Solomon to retire as CEO and President at the end of 2013 and will serve as Chairman to 2014 AGM and then become Chairman Emeritus.

Forest Laboratories, Inc. announced that Howard Solomon will retire as Chief Executive Officer and President, effective December 31, 2013. Subject to the same nominating and election processes annually as all directors, Mr. Solomon is expected to remain as Chairman through the 2014 Annual General Meeting (AGM), at which time another Chairman will be elected. Mr. Solomon will retain the title of Chairman Emeritus after the 2014 AGM and has agreed to serve as Senior Advisor to the Company following his retirement as CEO and President. Mr. Solomon has served as CEO since 1977, Chairman since 1998 and President since 2010.

As previously disclosed, an independent committee of Forest’s Board has been engaged in a succession planning process, including evaluating internal and external candidates. With Mr. Solomon’s retirement announcement, the Board has determined to bring the process to a close and expects to name a successor before the end of the year. The committee is being assisted by Spencer Stuart, a leading executive search firm.

Kenneth E. Goodman, Presiding Independent Director, said, “On behalf of the Board and the entire company, we would like to express our appreciation for Howard’s dedication, strategic vision and immeasurable contributions to Forest and its shareholders for nearly 50 years, 36 of those years as CEO. Under Howard’s leadership, Forest has evolved from a small-scale producer of vitamin pills into an innovative and fully integrated pharmaceutical company with a market capitalization of over $10 billion and a proud history of innovation, strong execution and delivering value for shareholders. Today, with the launches of a new generation of products, all advanced under Howard’s stewardship, Forest is positioned to build on this success. We are delighted that Howard is available to continue to serve Forest as Chairman through to the 2014 annual meeting and as a Director and Senior Advisor to the Company following his retirement as CEO and President.”

Gerald M. Lieberman, a member of the independent committee overseeing succession planning, said, “We have been actively engaged in the succession planning process for some time and agree with Howard that now is the right time to begin the transition to new leadership. There is no question that Howard has been an extraordinary chief executive. Our mission and focus now is to find the right CEO to take our products forward and build on the platform that Howard helped put in place. We appreciate his clear commitment to ensuring the smoothest possible transition.”

Mr. Solomon said, “I recognize that the time has come for me to retire from the full time responsibility of running Forest Laboratories. I will be 86 this August and I think the company is entitled to the rigorous assurances of continuity that a younger chief executive can provide. I have agreed to serve Forest as an advisor and, if elected, as a Director for the next several years. Above all, I do deeply love Forest and so many of its executives and employees with whom I have worked for so many years. It is thanks to the support and tireless effort of our extraordinarily talented employees, past and present, that we have been able to build a dynamic company with a diversified product portfolio and late-stage pipeline that is truly unrivaled in the industry. We have many opportunities ahead. In the coming months, I look forward to working with the Board and new CEO, when identified, on a seamless handover of my responsibilities and to continuing my service to Forest as a board member and Senior Advisor.”

Mr. Solomon began his career as an attorney at leading law firms in New York and joined Forest in 1964 as a director and secretary of the Board, while serving as outside counsel for the Company. He became CEO of Forest in 1977 and Chairman in 1998. Mr. Solomon is a Trustee of the New York Presbyterian Hospital and previously served on the Board of Cold Spring Harbor Laboratories. He is currently a member of the Executive Committee of the Board of Directors of the Metropolitan Opera and Chairman of its Finance Committee, a Director and former Chairman of the New York City Ballet and a Director Emeritus of Lincoln Center. Mr. Solomon graduated from the City College of New York and holds a J.D. from Yale University.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!